<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

 




 LSX Nordic Congress-1

Nasdaq Offices | Stockholm | Sweden
August 28-29, 2019
#LSXNORDIC

Showcasing Companies Already Confirmed!

 
AnnexinAnnexin
Ny logga CantargiaNy logga Cantargia
cereno-scientific-logotype
immunicum

Presenter
Jamal Al Mosleh, CEO

Company Bio

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for treatment of various cardiovascular diseases, which are currently the most common cause of death. 

Read More

Founded: 

2014


Sweden

 

Presenter
Göran Forsberg, CEO

Company Bio

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.


Read More

Founded: 
2010


Sweden

Presenter
Sten Sörensen, CEO

Company Bio

Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. 



Read More


Founded: 
2012


Sweden

Presenter
Carlos De Sousa, CEO

Company Bio

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer.


Read More

Founded: 
2002


Sweden

DOWNLOAD THE BROCHURE